<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Study on the treatment of 50 cases of <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (by applying beta-receptor blocking drug <z:chebi fb="2" ids="8499">propranolol</z:chebi>) and the control group of 55 cases revealed that the mortalities of the therapeutic group and the control group were respectively 4% and 9.2% (P less than 0.05) the incidences of the <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> were 2% and 10.6% (P less than 0.01) and those of the <z:hpo ids='HP_0011675'>abnormal electrocardiograms</z:hpo> were 6% and 21.8% (P less than 0.01) </plain></SENT>
<SENT sid="1" pm="."><plain>The differences between the two group were significant </plain></SENT>
<SENT sid="2" pm="."><plain>The function of <z:chebi fb="2" ids="8499">propranolol</z:chebi> may be associated with the sudden increase of <z:chebi fb="2" ids="33567">catecholamine</z:chebi> after <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> and there for the drug has the function of protection of the cardiac muscle and prevention of the <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>